Evaluation of the in vitro activity of daptomycin against 19615 clinical isolates of Gram-positive cocci collected in North American hospitals (2002-2005)

被引：56

作者：

Pfaller, Michael A.

Sader, Helio S. ^{[1
]}

Jones, Ronald N.

机构：

[1] JML Labs, N Liberty, IA 52317 USA

[2] Univ Iowa, Iowa City, IA 52242 USA

[3] Univ Fed Sao Paulo, Div Infect Dis, BR-04023900 Sao Paulo, Brazil

[4] Tufts Univ, Sch Med, Boston, MA 02111 USA

来源：

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE | 2007年 / 57卷 / 04期

关键词：

daptomycin; gram-positive infections; Staphylococcus aureus; susceptibility;

D O I：

10.1016/j.diagmicrobio.2006.10.007

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

We evaluated the antimicrobial activity of daptomycin against 19 615 clinical strains consecutively collected by numerous centers located across the United States and Canada (2002-2005). Daptomycin was very active against all indicated species (>99% susceptible), with the highest MIC results being 2, 8, 0.5, and 1 mu g/mL for staphylococci, enterococci, beta-hemolytic streptococci, and viridans group streptococci, respectively, and no significant loss in potency was observed over the period studied. (c) 2007 Elsevier Inc. All rights reserved.

引用

收藏

页码：459 / 465

页数：7

相关论文

共 32 条

[1] Pharmacokinetics of daptomycin in a critically ill adolescent with vancomycin-resistant enterococcal endocarditis [J].

Akins, RL ;

Haase, MR ;

Levy, EN .

PHARMACOTHERAPY, 2006, 26 (05) :694-698

[2] The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections [J].

Arbeit, RD ;

Maki, D ;

Tally, FP ;

Campanaro, E ;

Eisenstein, BI .

CLINICAL INFECTIOUS DISEASES, 2004, 38 (12) :1673-1681

[3] Daptomycin: Another novel agent for treating infections due to drug-resistant gram-positive pathogens [J].

Carpenter, CF ;

Chambers, HF .

CLINICAL INFECTIOUS DISEASES, 2004, 38 (07) :994-1000

[4] Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations [J].

Cha, R ;

Brown, WJ ;

Rybak, MJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (12) :3960-3963

[5] Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene [J].

Chang, S ;

Sievert, DM ;

Hageman, JC ;

Boulton, ML ;

Tenover, FC ;

Downes, FP ;

Shah, S ;

Rudrik, JT ;

Pupp, GR ;

Brown, WJ ;

Cardo, D ;

Fridkin, SK .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (14) :1342-1347

[6]

CLSI Clinical and Laboratory Standards Institute, 2006, M7A7 CLSI, V7th

[7]

CLSI Manual Clinical and Laboratory Standards Institute, 2006, M100S16 CLSI

[8]

*CUB PHARM INC, 2006, PACK INS CUB DAPT IN

[9] Pacemaker-induced Staphylococcus aureus mitral valve acute bacterial endocarditis complicated by persistent bacteremia from a coronary stent:: Cure with prolonged/high-dose daptomycin without toxicity [J].

Cunha, BA ;

Eisenstein, LE ;

Hamid, NS .

HEART & LUNG, 2006, 35 (03) :207-211

[10] In vitro activity of daptomycin against gram-positive European clinical isolates with defined resistance determinants [J].

Fluit, AC ;

Schmitz, FJ ;

Verhoef, J ;

Milatovic, D .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (03) :1007-1011

← 1 2 3 4 →